INNATE PHARMA (EPA:IPH) Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) announces an operating revenue of 4.3 million euros for the year 2010

Transparency directive : regulatory news

04/02/2011 17:45

PRESS RELEASE

INNATE PHARMA REPORTS ANNUAL OPERATING REVENUE OF 4.3 MILLION EUROS FOR 2010

Strong cash position with 34.5 million euros in cash, cash equivalents and
   current financial instruments as at the end of 2010

                    (IFRS unaudited provisional data)

Marseilles, France, February 4, 2011

Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH) announces
an operating revenue of 4.3 million euros for the year 2010. Turnover for the
year amounted 0.2 million euros.

The following table breaks down the operating revenue and compares 2010 to 2009:

In thousands of euros                           Fiscal year ended December 31,
                                                         2010          2009
Revenue from collaboration and licensing agreements      210          3,243
Non-core services                                          1             65
Turnover (A)                                             211          3,308
Government funding for research expenditures (B)       4,109          4,407
Operating revenue (A+B)                                4,320          7,715

Before reaching the marketing stage of its products, turnover of the Company is
composed mostly by revenue from collaboration and licensing agreements, and
notably from payments received for the achievement of pre-specified milestones
in the development of drug-candidates. Therefore, its turnover is not recurring
and may show substantial variations from one period to another.

In 2009, revenue from collaboration and licensing agreements mostly came from an
agreement signed with Novo Nordisk A/S in 2006 and ended in March 2009. In 2009
and 2010, the Company received additional research and development funding from
Novo Nordisk A/S for collaborative work performed on selected products that are
licensed to Novo Nordisk A/S. There was no turnover for the fourth quarter of
2010, compared to a turnover of 532 thousands euros for the fourth quarter of
2009.

Cash, cash equivalents and current financial instruments and financial
liabilities:

Cash, cash equivalents and current financial instruments of the Company amounted
to 34.5 million euros at December 31, 2010; at the same date, the financial
liabilities of the Company amounted 7.5 million euros, including 4.3 million
euros related to the twelve-year lease-financing agreement on the Company's main
premises, 2.5 million euros related to Oséo* grants and 0.7 millions euros for
other lease-financing agreements.

Innate Pharma will announce its annual results on March 2, 2011, before market
opens.
A meeting for fund managers, financial analysts and journalists will be held on
the same day, at 2:30pm (CET) in Paris. The slideshow will be available on the
Company's website.

* The French Innovation Agency

About Innate Pharma:

Innate Pharma S.A. is a biopharmaceutical company developing first-in-class
immunotherapy drugs for cancer and inflammatory diseases.

The Company specializes in the development of new monoclonal antibodies
targeting receptors and pathways controlling the activation of innate immunity
cells. It has two proprietary clinical-stage drug candidates: IPH 1101, a small
molecule agonist of gamma delta T cells, has achieved proof-of-concept in two
Phase IIa trials, in type C viral hepatitis and follicular lymphoma. IPH 2101,
an anti-KIR monoclonal antibody potentiating NK cells activation, is currently
in Phase II clinical trials in hematologic cancers. Innate Pharma is also
developing a preclinical portfolio of immunomodulatory or cytotoxic monoclonal
antibodies. Two of its preclinical programs in chronic inflammation have been
out-licensed to Novo Nordisk A/S.

Innate Pharma's key expertise is in immunopharmacology and antibody technology.
The Company has implemented in-house a large panel of molecular and cellular
assays and in vivo models for assessing the pharmacodynamics and
pharmacotoxicology of drug candidates. In addition, Innate Pharma has access to
a very large set of unique research tools in cellular immunology through its
worldwide network of scientific collaborations.

Incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006, Innate Pharma
is based in Marseilles, France, and had 85 employees as at December 31, 2010.

Learn more about Innate Pharma at www.innate-pharma.com.

Practical Information about Innate Pharma shares:
ISIN code           FR0010331421
Ticker code         IPH

Disclaimer:
This press release contains certain forward-looking statements. Although the
company believes its expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those anticipated.
For a discussion of risks and uncertainties which could cause the company's
actual results, financial condition, performance or achievements to differ from
those contained in the forward-looking statements, please refer to the Risk
Factors ("Facteurs de Risque") section of the Document de Reference prospectus
filed with the AMF, which is available on the AMF website
(http://www.amf-france.org) or on Innate Pharma's website.

This press release and the information contained herein do not constitute an
offer to sell or a solicitation of an offer to buy or subscribe to shares in
Innate Pharma in any country.

For additional information, please contact:

Innate Pharma                    Alize Public Relations
Laure-Hélène Mercier             Caroline Carmagnol
Director, Investor Relations     Phone: +33 (0)1 41 22 07 31
Phone: +33 (0)4 30 30 30 87      Mobile: +33 (0)6 64 18 99 59
investors@innate-pharma.com      caroline@alizerp.com

110204 2010 Operating revenue

INNATE PHARMA's latest news

05/04/2024 09:34

INNATE PHARMA (EPA:IPH) Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) announces an operating revenue of 4.3 million euros for the year 2010

Transparency directive : regulatory news

INNATE PHARMA's latest news

Other stories